NOV 03, 2016 12:00 PM PDT

Use of QIAGEN® Clinical Insight (QCI™) Interpret to Elucidate Precision in Breast Cancer Targeted Therapy

Speakers
  • Manager, Advanced Genomics Integrated Solutions
    Biography
      After completing in a B.S. in Biochemistry, Dr Deschênes obtained a Master in Pharmacology from University of Montréal, Canada focusing on the development of competitive antagonist for the Natriuretic Peptide Receptor B. She completed her Ph.D. in Biochemistry and Molecular Biology in 2008 at the Institute for Research in Immunology and Cancer (IRIC) in Montréal where she studied Breast Cancer by looking at the transcriptional regulation of estrogen receptor to the DNA through long-range regulation by estrogen. Dr Deschênes has been an author on numerous peer-reviewed articles and spoken on a variety of high-level panels, symposiums, and conference sessions.

      Dr. Deschênes joined QIAGEN in 2007 through Ingenuity Systems, now part of QIAGEN Bioinformatics and has since worked closely with customers and partner identifying insights in their NGS and expression analysis data as well helping the implementation of their clinical decision support software. She is a strong customer advocate thriving on partnering with customer to meet and exceed their needs. She recently obtained her Executive MBA on Market Strategy for a Next-Generation Sequencing Clinical Reporting Software from the Würzburg Universität, Germany while supporting the market entry of QIAGEN Clinical Insight Interpret.
    • Senior Scientist, Advanced Genomics Support; QIAGEN Bioinformatics
      Biography
        Dilhan Weeraratne is a cancer genomics scientist invested in leveraging the explosion of genomics data to transform cancer treatment and patient outcome. Dilhan has over a decade of experience in cancer genomics and precision oncology both in academic and industry settings.

        Dilhan obtained his PhD in neuroscience/molecular biology from University of Vermont in 2007. Subsequently, he joined Harvard Medical School and Broad institute, MIT to do postdoctoral research in medulloblastoma genomics. His work was instrumental in defining the currently WHO accepted molecular subgroups of Medulloblastoma. Dilhan's work on genomic landscape of medulloblastoma was published in the journal "Nature". Following his postdoctoral work, Dilhan transitioned to biopharma and worked at leading diagnostics companies including Thermo Fisher and N-of-One working on clinical interpretation and annotation of biomarkers in solid and hematological tumors, clinical reporting and developing pharmacogenomics biomarker knowledgebases. Dilhan Joined QIAGEN in May of 2016.

      Abstract

      Breast cancer is a complex heterogeneous disease, with each subtype characterized by distinct clinical features and molecular alterations. The heterogeneity of breast cancer has presented massive challenges for identifying appropriate treatment for each patient. Advances in next-generation sequencing (NGS) have presented unique treatment opportunities beyond stratification of patients by hormone receptor and epidermal growth factor receptor status. QIAGEN® Clinical Insight (QCI™ Interpret) is a web-based application for the annotation, classification, and reporting of actionable variants from NGS data in clinical genomics laboratories.

      Learning Objectives: 

      • Understand how QCI Interpret identifies molecular alterations that have direct treatment implications for patients, based on five real world clinical cases from TCGA.
      • Discover how the richness of the QIAGEN Knowledge Base and the versatility of QCI Interpret contribute to  presenting treatment options for patients.

      Show Resources
      You May Also Like
      JAN 23, 2020 9:00 AM PST
      C.E. CREDITS
      JAN 23, 2020 9:00 AM PST
      DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
      APR 07, 2020 8:00 AM PDT
      C.E. CREDITS
      APR 07, 2020 8:00 AM PDT
      DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
      MAY 08, 2020 10:00 AM PDT
      C.E. CREDITS
      MAY 08, 2020 10:00 AM PDT
      DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
      FEB 26, 2020 9:00 AM PST
      C.E. CREDITS
      FEB 26, 2020 9:00 AM PST
      DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
      JUN 09, 2020 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      JUN 09, 2020 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
      FEB 19, 2020 11:00 AM PST
      C.E. CREDITS
      FEB 19, 2020 11:00 AM PST
      DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
      Loading Comments...
      Show Resources